These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 23314304)
1. Circulating tumor cells as therapy-related biomarkers in cancer patients. Gorges TM; Pantel K Cancer Immunol Immunother; 2013 May; 62(5):931-9. PubMed ID: 23314304 [TBL] [Abstract][Full Text] [Related]
2. Clinical and biological significance of circulating tumor cells in cancer. Masuda T; Hayashi N; Iguchi T; Ito S; Eguchi H; Mimori K Mol Oncol; 2016 Mar; 10(3):408-17. PubMed ID: 26899533 [TBL] [Abstract][Full Text] [Related]
3. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322 [TBL] [Abstract][Full Text] [Related]
4. Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. Milano A; Mazzetta F; Valente S; Ranieri D; Leone L; Botticelli A; Onesti CE; Lauro S; Raffa S; Torrisi MR; Marchetti P Anal Cell Pathol (Amst); 2018; 2018():3506874. PubMed ID: 29682444 [TBL] [Abstract][Full Text] [Related]
5. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer. Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758 [TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. Sun YF; Yang XR; Zhou J; Qiu SJ; Fan J; Xu Y J Cancer Res Clin Oncol; 2011 Aug; 137(8):1151-73. PubMed ID: 21681690 [TBL] [Abstract][Full Text] [Related]
8. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372 [TBL] [Abstract][Full Text] [Related]
9. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition. Jiang S; Mao C; Jiang B; Tan Q; Deng B Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252 [TBL] [Abstract][Full Text] [Related]
10. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026 [TBL] [Abstract][Full Text] [Related]
11. Current progress in the clinical use of circulating tumor cells as prognostic biomarkers. Jin KT; Chen XY; Lan HR; Wang SB; Ying XJ; Abdi SM; Wang W; Hu ZM; Mou XZ Cancer Cytopathol; 2019 Dec; 127(12):739-749. PubMed ID: 31589381 [TBL] [Abstract][Full Text] [Related]
12. Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. Van Berckelaer C; Brouwers AJ; Peeters DJ; Tjalma W; Trinh XB; van Dam PA Eur J Surg Oncol; 2016 Dec; 42(12):1772-1779. PubMed ID: 27265041 [TBL] [Abstract][Full Text] [Related]
13. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells: biology and clinical significance. Lin D; Shen L; Luo M; Zhang K; Li J; Yang Q; Zhu F; Zhou D; Zheng S; Chen Y; Zhou J Signal Transduct Target Ther; 2021 Nov; 6(1):404. PubMed ID: 34803167 [TBL] [Abstract][Full Text] [Related]
15. Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. Papadaki MA; Kallergi G; Zafeiriou Z; Manouras L; Theodoropoulos PA; Mavroudis D; Georgoulias V; Agelaki S BMC Cancer; 2014 Sep; 14():651. PubMed ID: 25182808 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Chistiakov DA; Chekhonin VP Exp Mol Pathol; 2018 Oct; 105(2):166-174. PubMed ID: 30028961 [TBL] [Abstract][Full Text] [Related]
17. Progress in circulating tumor cell capture and analysis: implications for cancer management. Balic M; Lin H; Williams A; Datar RH; Cote RJ Expert Rev Mol Diagn; 2012 Apr; 12(3):303-12. PubMed ID: 22468820 [TBL] [Abstract][Full Text] [Related]
18. Circulating tumour cells in metastatic head and neck cancers. Kulasinghe A; Perry C; Jovanovic L; Nelson C; Punyadeera C Int J Cancer; 2015 Jun; 136(11):2515-23. PubMed ID: 25111594 [TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619 [TBL] [Abstract][Full Text] [Related]
20. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion. Wang H; Stoecklein NH; Lin PP; Gires O Oncotarget; 2017 Jan; 8(1):1884-1912. PubMed ID: 27683128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]